The future of lymphoma treatment – combining new therapies with molecular diagnosis
The importance of multiple myeloma foundations and a patient story
Paul Richardson et al.
Developments in prognostic factors of acute myeloid leukemia (AML)
Gert J. Ossenkoppele
Recent developments in the mutational landscape and molecular basis of AML
What role will minimal residual disease testing play in multiple myeloma?